Immunic's (IMUX) Buy Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a buy rating for Immunic (NASDAQ:IMUX) and set a price objective of $10.00 for the stock.
• Immunic reported a quarterly earnings loss of ($0.20) EPS, missing analysts' expectations of ($0.18) EPS, with predictions for the current fiscal year indicating a total -0.94 EPS.
• Institutional ownership in Immunic has recently increased significantly, with strong increases from several firms, including a 678.1% increase by Aberdeen Group plc.

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $10.00 price objective on the stock.

Immunic Stock Performance

NASDAQ IMUX opened at $0.88 on Thursday. The company has a market capitalization of $86.72 million, a P/E ratio of -0.94 and a beta of 1.44. Immunic has a one year low of $0.56 and a one year high of $1.73. The stock has a 50 day moving average price of $0.90 and a 200-day moving average price of $0.93.

Immunic (NASDAQ:IMUX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). As a group, equities analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Trading of Immunic

A number of institutional investors have recently bought and sold shares of the stock. Aberdeen Group plc lifted its position in Immunic by 678.1% in the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company's stock worth $5,750,000 after buying an additional 7,184,457 shares during the last quarter. Focus Partners Wealth increased its stake in Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock worth $2,816,000 after purchasing an additional 415,104 shares during the period. 683 Capital Management LLC increased its stake in Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock worth $981,000 after purchasing an additional 200,000 shares during the period. Millennium Management LLC increased its stake in Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after purchasing an additional 479,846 shares during the period. Finally, Jane Street Group LLC increased its stake in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares during the period. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.